The Institute for the Commercialization of Public Research announced today that it has finalized a funding agreement with Heart Genomics, LLC, an early-stage biotechnology company focused on providing non-invasive, genomic-based, clinical diagnostic tests for patients with heart failure. The Institute works with Florida’s research universities and institutions to support new company creation and job growth, and the program bridges funding gaps, enabling recipients to reach critical milestones and attract additional private investment capital.
Heart Genomics is at the forefront of the burgeoning molecular diagnostics market. The new diagnostic tests will provide personalized and individualized information to each patient and their physician through the genomic analysis of the patient's heart tissue or blood sample, and with this information, the heart patient and physician can make substantially improved and clear treatment decisions.
To read the full, original article click on this link: Florida Institute for the Commercialization of Public Research Web Site
